Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data
Erasca shares surged 10.5% to $8.29 midday Wednesday after early Phase 1 trial data showed two confirmed and one unconfirmed partial tumor responses for ERAS-0015, with no dose-limiting toxicities reported. H.C. Wainwright and Clear Street raised price targets to $11, Stifel to $10, citing strong early results and a clean safety profile.
